Soluble interleukin 2 receptor ( sIL-2R ) during chemotherapy of the lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002
Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012
Relationship between interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-alpha), C-reaktive protein (CRP), albumin (ALB) and alkaline phosphatase (ALP) in bronchoalveolar lavage fluid (BALF) of patients with interstitial lung disease Source: Eur Respir J 2006; 28: Suppl. 50, 98s Year: 2006
Interleukin -18 (IL-18) and tumor necrosis factor (TNF) in sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 434s Year: 2002
Evaluation levels of pro-inflammatory cytokines tumour necrosis factor (TNF)-alpha and interleukin (IL) 1-beta in small cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 233s Year: 2001
Levels of interleukins IL-4, IL-6, IL-8 and TNFa in sera of patients with tuberculosis before and during treatment Source: Eur Respir J 2002; 20: Suppl. 38, 556s Year: 2002
Decreased levels of CXC angiogenic chemokines (IL-8, ENA-78 and GRO-α) in BALF after interferon gamma-1b treatment in IPF patients Source: Eur Respir J 2005; 26: Suppl. 49, 267s Year: 2005
YKL-40, soluble IL-2 receptor, ADA and neopterin: comparison of markers of sarcoidosis activity Source: Annual Congress 2009 - Sarcoidosis in review Year: 2009
The level of IL-10, IL-12 and soluble Fas (sFas) in patients with non-advanced and advanced NSCLC Source: Eur Respir J 2006; 28: Suppl. 50, 103s Year: 2006
Role of the TNF-alpha and its 55 (sTNF-R1) and 75 (sTNF-R2) kDa receptors in bronchial hyperresponsivenes Source: Eur Respir J 2002; 20: Suppl. 38, 191s Year: 2002
Pro- and anti-inflammatory cytokines TNF-alpha, IFN-gamma, IL-10 and TGF-beta1 levels in blood serum as markers of plasmaferesis success and inflammation activity in lung sarcoidosis (LS) Source: Eur Respir J 2006; 28: Suppl. 50, 676s Year: 2006
Interferon (-alpha, -beta, and -omega) receptor 2 (IFNAR2) is a prognostic biomarker for lung cancer Source: Annual Congress 2011 - Innovative diagnostic methods for lung cancer Year: 2011
Clinical value of soluble interleukine-2 receptor (sIL-2R) serum level examination in the pulmonary sarcoidosis (PS) Source: Eur Respir J 2003; 22: Suppl. 45, 226s Year: 2003
Levels of TNF-alpha, IL-6, sICAM-1, sVCAM-1 in NSCLC patients plazma Source: Annual Congress 2008 - Novel mechanisms and targets of molecular pulmonary pathology Year: 2008
The clinical significance of serum osteoprotegerin (OPG) and pro-gastrin-releasing peptide (ProGRP) concentrations in lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 318s Year: 2004
Lung expression of interleukin-13 (IL-13) and interferon gamma (IFNg) in emphysema in human Source: Eur Respir J 2002; 20: Suppl. 38, 584s Year: 2002
Prognostic meaning of interleukin-8 (IL-8) and interleukin-10 (IL-10) during the development of postoperative pneumonias Source: Eur Respir J 2005; 26: Suppl. 49, 633s Year: 2005
Upregulation of interleukin 13 receptor alpha 2 (IL-13RA2) expression in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 267s Year: 2005
The neoadjuvant therapy of NSCLC down-regulates serum levels of growth factors (VEGF, bFGF, TGF-beta) with no effect on apoptosis (CD95L) and local tumour invasiveness markers (TIMP-1) Source: Eur Respir J 2006; 28: Suppl. 50, 386s Year: 2006
Changes in the quantity of 1b-interleukin (IL-1b), tumor necrosis factor-a (TNF-a) and interferon-g (IF-g) in evaluation of the effectiveness of treatment of tuberculosis by DOTS Source: Eur Respir J 2004; 24: Suppl. 48, 486s Year: 2004